Full Press Release Details
IDEAYA Biosciences and Cancer Research UK Announce Partnership Agreement to Develop Small Molecule Inhibitors of PARG.
IDYA
IDEAYA Biosciences and Cancer Research UK Announce Partnership Agreement to Develop Small Molecule Inhibitors of PARG
Key Takeaway: IDEAYA Biosciences and Cancer Research UK Announce Partnership Agreement to Develop Small Molecule Inhibitors of PARG
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma